Meridian does cover GLP-1 medications, but what the plan will actually pay for depends on why the drug is prescribed and which state you live in. For type 2 diabetes, GLP-1 drugs are covered across Meridian’s Michigan, Illinois, and Ohio plans with prior authorization. For weight loss alone, Illinois Medicaid excludes these drugs entirely, and Michigan Medicaid sharply restricted coverage on January 1, 2026. The question of whether Meridian covers GLP-1 therapy, in other words, has a different answer for Ozempic prescribed for diabetes than for Wegovy prescribed for obesity.
Diabetes Coverage Across Meridian Plans
If you have type 2 diabetes, Meridian covers the full GLP-1 class, though every product requires prior authorization. Michigan’s Meridian formulary lists Trulicity, Ozempic, Mounjaro, Rybelsus, Victoza, Byetta, Bydureon BCise, and Adlyxin under its diabetes category.1Meridian Health Plan of Michigan. GLP-1 Agonists Bulletin
Illinois adds specific step-therapy rules. You need a confirmed type 2 diabetes diagnosis with an HbA1c of 7% or higher documented within the past three months. For oral semaglutide (Rybelsus), you must have tried and failed at least three consecutive months of metformin. For Ozempic in patients with cardiovascular disease or risk factors, both Trulicity and Victoza must be tried and failed first. Non-preferred GLP-1 agents require documented failure of two preferred options. Initial approvals run six months, and a renewal of up to twelve months requires documentation of a positive treatment response.2Meridian Health Plan of Illinois. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Clinical Policy
Meridian will not pay for two GLP-1 drugs at once. As of mid-2025, Illinois pharmacy claims are also rejected if you try to combine a GLP-1 with a DPP-4 inhibitor; the DPP-4 drug must be discontinued.3Meridian Health Plan of Illinois. Preferred Drug List Updates
Weight Loss Coverage in Illinois
Meridian’s Illinois Medicaid plan does not cover GLP-1 medications for weight loss. The clinical policy states that “weight loss is a benefit exclusion and is not a covered benefit,” and any request for a GLP-1 for an indication other than type 2 diabetes is denied.2Meridian Health Plan of Illinois. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Clinical Policy This reflects a state Medicaid decision rather than a Meridian-specific one. Federal law permits states to exclude weight-loss drugs from Medicaid formularies, and Illinois does.4Real Chemistry. State-by-State Analysis of Medicaid Coverage for GLP-1 Weight Loss
Weight Loss Coverage in Michigan After January 2026
Michigan Medicaid used to offer broader coverage for GLP-1 obesity medications. That changed on January 1, 2026, after Public Act 22 of 2025 cut $240 million in pharmaceutical appropriations for GLP-1 drugs and tightened the rules.5Michigan Public. Michigan Cuts Off Weight Loss Drugs for Most Medicaid Patients6Michigan Legislature. House Bill 4706
To get Wegovy, Zepbound, Saxenda, or generic liraglutide approved for obesity through Meridian’s Michigan Medicaid plan now, you must meet all four of these conditions:
- A BMI of 40 or greater (morbid obesity).
- Documented failure of all other clinically appropriate weight-loss approaches, including a trial and failure of the preferred anti-obesity agents on Michigan’s Preferred Drug List (phentermine and Qsymia).
- Prescriber attestation that the GLP-1 medication is necessary to avert the need for higher-cost bariatric surgery.
- Prior authorization approval through Meridian using Michigan Department of Health and Human Services criteria.
The rules apply to every Michigan Medicaid beneficiary, whether in Meridian’s managed care plan or in fee-for-service. Saxenda and Wegovy also moved to non-preferred status on the state’s Preferred Drug List, carrying a $3 copayment for non-exempt beneficiaries outside managed care.7Michigan Department of Health and Human Services. L-Letter L 25-73: Update of Pharmacy Drug Coverage for Treatment of Obesity
Other FDA-Approved Uses Still Covered
Michigan’s restriction targets obesity treatment specifically. Coverage for GLP-1 medications prescribed for other FDA-approved conditions did not change. Zepbound remains covered for moderate to severe obstructive sleep apnea. Wegovy remains available for patients with established cardiovascular disease or severe liver disease.8University of Michigan Medical Research. Expert Q&A: Michigan Medicaid’s New Limits on GLP-1 Weight Management Medications Michigan has said that roughly 80% of existing GLP-1 recipients in its Medicaid population have other qualifying medical conditions and should retain coverage on those grounds.9U.S. News & World Report. Michigan to Limit Medicaid Coverage for Weight Loss Drugs
Existing Authorizations and Appeals
If you had an active prior authorization for a GLP-1 obesity prescription before January 1, 2026, Michigan allowed that approval to run out its remaining six-month term. Renewals after that date are reviewed under the new, stricter criteria.10Meridian Health Plan of Michigan. GLP-1 Benefit Reduction Bulletinp>
A denial is not the end of the road. In one documented case, a Meridian Medicaid member in Michigan with obesity, non-alcoholic fatty liver disease, and osteoarthritis was denied continued Wegovy coverage. Meridian upheld the denial on internal review in June 2025. An independent review organization then found the member had met the plan’s renewal criteria by maintaining at least a 5% weight loss, and in August 2025 a senior deputy director at Michigan’s Department of Insurance and Financial Services ordered Meridian to reverse the denial and authorize coverage retroactively.11Michigan Department of Insurance and Financial Services. Meridian External Review Decision, File No. 238078 If Meridian denies a GLP-1 request you believe meets the criteria, the adverse determination letter will explain your appeal rights, including the option of external review.
How Prior Authorization Works
You do not submit the prior authorization yourself. Your prescriber completes and sends the PA request to Meridian, which reviews it against medical necessity and the applicable plan criteria. Standard requests receive a written decision within five calendar days; urgent requests are decided within 48 hours.12Meridian Health Plan of Illinois. Prior Authorization A denial letter will set out the reason and your appeal rights. Michigan providers can also use online pre-authorization check tools through Meridian’s provider portal for Medicaid, Medicare-Medicaid, and Ambetter plans.1Meridian Health Plan of Michigan. GLP-1 Agonists Bulletin
Medicare and Marketplace Plans
As of January 1, 2026, Meridian’s Medicare-Medicaid Plan became Wellcare Meridian Dual Align (HMO D-SNP). The full formulary is published online and updated monthly, and you can use the plan’s drug search tool or call 1-844-536-2180 to confirm whether a specific GLP-1 drug is covered and what restrictions apply.13Wellcare Meridian. Wellcare Meridian Dual Align Formulary If a drug you need is not on the formulary, you can request a coverage determination with a doctor’s statement and an exception form.14Meridian Medicare-Medicaid Plan. Formulary
On the marketplace side, Meridian operates as Ambetter. The 2025 Ambetter from Meridian formulary in Michigan lists Contrave (a non-GLP-1 anti-obesity drug) as covered with prior authorization but does not appear to include Wegovy, Zepbound, or Ozempic on the pages reviewed.15Ambetter from Meridian. 2025 Formulary If you have an Ambetter plan, check the current formulary directly or call the plan before assuming a GLP-1 is covered.